Britain and America have forged a key bilateral deal that will keep zero duties on British medicine shipments being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This move guarantees that tariffs on these vital products will be held at zero for a duration of the next three years.
This agreement follows earlier threats to hike tariffs on branded pharmaceutical products, with figures mentioned up to one hundred percent.
"This arrangement between the Britain bolsters the international landscape for new treatments and introduces long-overdue balance to transatlantic drug exports," a release said.
Commercial Importance
Drugs represent one of the the United Kingdom's most significant exports to the US, which is clearly the largest market for large British pharmaceutical firms.
Statistics reveal that in the 12 months prior to the third quarter, the UK shipped drugs valued at £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects jobs, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," a government official remarked.
Detailed UK Commitments
The agreement entails several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to increase total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, rebates exceeded 20%.
Industry Background
The pact comes amid a long-running tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
This friction were intensified by assertions that US patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the previous ten-year period.
